Women's reproductive and lifestyle characteristics can be linked to different invasive breast cancer subtypes. Data on 2544 breast cancer cases, presented in the open access journal Breast Cancer Research, suggests that traditional risk factors for development of the condition are associated with different kinds of tumor.
Marilyn Kwan from Kaiser Permanente Division of Research, California, led a team of researchers who used data from the LACE (Life After Cancer Epidemiology) and Pathways studies to investigate the characteristics of women with different breast cancer subtypes: luminal A, luminal B, triple negative and Her2-overexpressing. She said, "These varying associations by subtype lend further support to the growing evidence base that breast cancer is a heterogeneous disease defined by estrogen receptor, progesterone receptor, and Her2 expression with distinct etiologic pathways and prognoses".
The researchers found that patients with luminal B tumors were generally younger at diagnosis than those with luminal A and were less likely to consume alcohol, use HRT or use oral contraceptives. Compared to luminal A cases, triple negative cases tended to be African American, younger at diagnosis and overweight/obese if premenopausal. Her2-overexpressing cases were also more likely to be seen in younger patients than luminal A cases and were more likely to be Hispanic or Asian.
Kwan concludes, "Future research should focus on refinement of tumor subtypes in order to best elucidate how the risk factors may vary. Important modifiable factors that may be related to the development of specific tumor subtypes include obesity in the case of triple negative cancers and alcohol consumption for luminal B tumors".
Notes to Editors
1. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors
Marilyn L Kwan, Lawrence H Kushi, Erin Weltzien, Benjamin Maring, Susan E Kutner, Regan S Fulton, Marion M Lee, Christine B Ambrosone and Bette J Caan
Breast Cancer Research (in press)
During embargo, article available here: http://breast-cancer-research.com/imedia/1861405069246662_article.pdf?random=648884
After the embargo, article available at the journal website: http://breast-cancer-research.com/
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at firstname.lastname@example.org on the day of publication.
2. Breast Cancer Research (http://breast-cancer-research.com/home/) is an international, peer-reviewed online journal, publishing original research, reviews, commentaries and reports. Research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition, the journal publishes clinical studies with a biological basis, including Phase I and Phase II trials. Breast Cancer Research has an Impact Factor of 4.37.
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.